China SXT Pharmaceuticals, Inc. (SXTC)
Stock research & financials
Reported business results for SEC issuer CIK 0001723980. These figures are automatically extracted and have not received the manual review applied to our 22 reviewed profiles.
The annual figures, at a glance.
Annual period ended 2026-03-31. These are historical business results, not current prices or forecasts.
Net profit / loss
-6.21mUSDProfit after expenses; a negative figure is a loss.Original filing ↗Operating cash flow
-4.02mUSDCash generated or used by business operations.Original filing ↗Debt
UnavailableNot verified in this snapshot. Check the balance sheet in the original filing.Unavailable does not mean zero. Rounded figures are for scanning; detailed values and source dates follow below.
Inspect reported figures
Choose a measure, check the periods and follow the filing. This uses the same historical snapshot as the figures above.
Revenue
Reported unit: USD. Amounts below are not share prices.
Bars show absolute magnitude. Negative amounts keep their minus sign; zero has no bar.
| Period | Period dates | Amount |
|---|---|---|
| 2026-03-31 | 2025-04-01 to 2026-03-31 | 1,138,052 |
One period is available here. No change or trend has been inferred.
Open the original filing for this evidence →
Check the filing for restatements, accounting definitions and newer reports. These figures alone do not establish whether a stock is suitable.
Sector & issuer classification
Reported industry: Pharmaceutical Preparations (SIC 2834). Sector evidence ↗ · checked 2026-11-10. Official SEC SIC mapped to editorial discovery group. A sector is a discovery group, not a security-type or current trading-status verification.
Explore the chart and market statistics
Dividend yield & key stats
Loading statistics for SXTC…
- Dividend yield
- Unavailable until provider data loads
- Market cap
- Unavailable until provider data loads
- P/E ratio
- Unavailable until provider data loads
- Earnings per share
- Unavailable until provider data loads
Missing data does not mean zero. Coverage varies by listing.
Sources, dates and coverage
Snapshot checked 2026-10-17. This is dated annual data, not a live price, forecast, valuation or confirmation of the latest filing. An issuer may have several listed securities; these are company figures, not separate financial statements for each listing.
Reporting periods and units appear with each figure. Missing measures remain unavailable. Filing dates are shown where supplied by the source; otherwise check the original filing before relying on it.
Check the issuer’s SEC filings ↗China SXT Pharmaceuticals, Inc.: annual results at a glance
The most recent retained annual period ended 2026-03-31. 4 financial measures are available in this snapshot. Figures below describe the business; they are not a share price.
Changes between retained annual periods
Periods of similar length and matching units only. Restatements, acquisitions and accounting changes can affect comparisons; read the filings for context.
Revenue
2025-03-31 → 2026-03-31
1,740,907 → 1,138,052 USD
-34.63% change
Bar lengths show magnitude; signed values are labelled above.Check the underlying filing ↗Net income / loss
2025-03-31 → 2026-03-31
-3,303,652 → -6,205,085 USD
Percentage change is not shown when the earlier value is zero or negative.
Bar lengths show magnitude; signed values are labelled above.Check the underlying filing ↗Operating cash flow
2025-03-31 → 2026-03-31
-2,345,333 → -4,017,456 USD
Percentage change is not shown when the earlier value is zero or negative.
Bar lengths show magnitude; signed values are labelled above.Check the underlying filing ↗Diluted earnings per share
2025-03-31 → 2026-03-31
-348.17 → -9.13 USD/shares
Percentage change is not shown when the earlier value is zero or negative.
Bar lengths show magnitude; signed values are labelled above.Check the underlying filing ↗SXTC stock research: questions answered
Use these dated financial results as a starting point, then check the original reports for context.
What was China SXT Pharmaceuticals, Inc.'s reported revenue?
For the annual period ended 2026-03-31, China SXT Pharmaceuticals, Inc. reported revenue of 1,138,052 USD. This is a historical reported result, not a forecast.
Read the original filing for this figure ↗What was China SXT Pharmaceuticals, Inc.'s reported net income?
For the annual period ended 2026-03-31, China SXT Pharmaceuticals, Inc. reported net income of -6,205,085 USD. This is a historical reported result, not a forecast.
Read the original filing for this figure ↗What was China SXT Pharmaceuticals, Inc.'s reported operating cash flow?
For the annual period ended 2026-03-31, China SXT Pharmaceuticals, Inc. reported operating cash flow of -4,017,456 USD. This is a historical reported result, not a forecast.
Read the original filing for this figure ↗What was China SXT Pharmaceuticals, Inc.'s reported diluted earnings per share?
For the annual period ended 2026-03-31, China SXT Pharmaceuticals, Inc. reported diluted earnings per share of -9.13 USD/shares. This is a historical reported result, not a forecast.
Read the original filing for this figure ↗Does this page show SXTC's live share price?
No. This page covers historical company financial results. It does not provide a live share price, current valuation or buy/sell recommendation.
Find China SXT Pharmaceuticals, Inc.'s SEC filings and check for newer reports ↗
Understand the figures before comparing stocks
Sources, checks and calculation methods →
Revenue, profit and cash flow explained →
Annual period ended 2026-03-31
2025-04-01 – 2026-03-31 · Reporting currency USD · filing date: check original source
Revenue
1,138,052USD
Original filing for this figure ↗Net income / loss
-6,205,085USD
Original filing for this figure ↗Operating cash flow
-4,017,456USD
Original filing for this figure ↗Diluted earnings per share
-9.13USD/shares
Original filing for this figure ↗Annual period ended 2025-03-31
2024-04-01 – 2025-03-31 · Reporting currency USD · filing date: check original source
Revenue
1,740,907USD
Original filing for this figure ↗Net income / loss
-3,303,652USD
Original filing for this figure ↗Operating cash flow
-2,345,333USD
Original filing for this figure ↗Diluted earnings per share
-348.17USD/shares
Original filing for this figure ↗Annual period ended 2024-03-31
2023-04-01 – 2024-03-31 · Reporting currency USD · filing date: check original source
Revenue
1,928,497USD
Original filing for this figure ↗Net income / loss
-3,098,532USD
Original filing for this figure ↗Operating cash flow
-1,928,053USD
Original filing for this figure ↗Diluted earnings per share
-4,285.66USD/shares
Original filing for this figure ↗Continue your research
Check the original reports, investigate debt, cash flow and dilution, and use the workspace to save your own notes.
